EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Akeso's Enterprise Value is HK$40,198 Mil.
Akeso's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,220 Mil. Therefore, Akeso's EV-to-EBIT for today is 18.11.
The historical rank and industry rank for Akeso's EV-to-EBIT or its related term are showing as below:
HKSE:09926'
s EV-to-EBIT Range Over the Past 10 Years
Min: -128.64 Med: -23.13 Max: 18.58
Current: 17.85
During the past 6 years, the highest EV-to-EBIT of Akeso was 18.58. The lowest was -128.64. And the median was -23.13.
HKSE:09926's EV-to-EBIT is ranked worse than 64.84% of 438
companies
in the Biotechnology industry
Industry Median: 8.725
vs HKSE:09926: 17.85
The historical data trend for Akeso's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Akeso's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Akeso's EV-to-EBIT falls into.
Akeso's current Enterprise Value is HK$40,198 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,220 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso (HKSE:09926) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Akeso's Enterprise Value for the quarter that ended in Dec. 2023 was HK$36,753 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,220 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Akeso's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09926 has been successfully added to your 